The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

| 1.  | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |

| Yes, at the scoping workshop a patient expert stated that |

1) Type 2 diabetes is particularly prevalent among people of South Asian family origin and

2) The vast majority of UK Muslim population have South Asian family background who have a high prevalence of type 2 diabetes. NICE clinical guidelines did not make any recommendation for treatment options for people with type 2 diabetes mellitus who may wish to fast during the month of Ramadan.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

1) Issues related to differences in prevalence or incidence of a disease between population groups cannot be addressed in a technology appraisal. NICE is committed to avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity.

2) Prolonged fasting can affect blood sugar levels and treatment in these patients needs to be altered accordingly. Lack of guidance for treating diabetic patients who may wish to fast is an important clinical issue which may be better addressed in the relevant clinical guideline. However, this was not considered to be an equality issue that can be addressed in a Technology Appraisal.

It was therefore considered that these are not equality issues and that these do not need to be reflected in the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft remit or draft scope are required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified.

**Approved by Associate Director (name):** ...Janet Robertson......

**Date:** 18 February 2014